Genitourinary Cancers

Vote in OncLive's polls to share which lung and genitournary cancer abstracts you're most anticipating at the 2025 ESMO Congress.

The FDA approved subcutaneous pembrolizumab for use in adult and pediatric solid tumor indications approved for intravenous pembrolizumab.

Sumanta Pal, MD, FASCO, explained the rationale for evaluating atezolizumab vs placebo for the treatment of patients with high-risk localized RCC.

Alexander Chehrazi-Raffle, MD, discusses the rationale for a subgroup analysis of the TiNivo-2 of tivozanib with/without nivolumab in mRCC.

Jad Chahoud, MD, MPH, discusses the safety profile of ALLO-316 for the treatment of patients with advanced clear cell renal carcinoma.

Jad Chahoud, MD, MPH, discusses the CAR T-cell therapy ALLO-316 in advanced clear cell renal carcinoma (ccRCC).

The top 5 OncLive videos of the week cover insights in sarcoma, colorectal cancer, acute lymphoblastic leukemia, renal cell carcinoma.

Jad Chahoud, MD, MPH, discusses preliminary efficacy data with zanzalintinib plus nivolumab with/without relatlimab in untreated, advanced clear cell RCC.

Naomi B. Haas, MD, details the rationale for evaluating adjuvant pembrolizumab monotherapy for the treatment of patients with clear cell RCC.

Hans Hammers, MD, PhD, discusses factors that may influence depth of response to IO/TKI or IO/IO therapy in advanced clear cell renal cell carcinoma.

Joseph Vento, MD, discusses the importance of using somatic NGS to guide treatment decision-making for patients with non–clear cell RCC.

Jad Chahoud, MD, MPH, discusses the background and rationale for evaluating zanzalintinib plus nivolumab with or without relatlimab in ccRCC.

Joseph Vento, MD, discusses the importance of refining RCC classification standards to improve the field’s understanding of the disease’s heterogeneity.

Nemvaleukin alfa produced a disease control rate of 50% in advanced melanoma and RCC.

David A. Braun, MD, PhD, discusses the need for more tailored treatments that improve tumor-specific T-cell infiltration in chromophobe RCC.

David A. Braun, MD, PhD, outlines differences in the tumor biology and immune phenotypes of chromophobe and clear cell renal cell carcinoma.

Sumanta Kumar Pal, MD, FASCO, discusses future directions using genomic data from the phase 3 IMmotion010 trial.

The top 5 OncLive videos of the week cover insights in renal cell carcinoma, glioma, multiple myeloma, and ovarian cancer.

Although chromophobe RCC has an immune-cold environment, ferroptosis induction may be a promising target for managing tumor resistance in this subtype.

Sumanta Kumar Pal, MD, FASCO, discusses findings from a genomic analysis of patients with high-risk, resected RCC treated with checkpoint inhibitors.

Alan Tan, MD, discusses how a trial analysis of ipilimumab plus nivolumab in metastatic ccRCC informs strategies for optimal immunotherapy sequencing.

The top 5 OncLive videos of the week cover insights in ovarian cancer, RCC, melanoma, non–small cell lung cancer, and non–muscle-invasive bladder cancer.

Glofitamab received a CRL from the FDA in R/R DLBCL, ODAC voted against belantamab mafodotin in R/R multiple myeloma, and more.

Treatment with casdatifan in combination with cabozantinib produced responses and was safe in patients with pretreated clear cell renal cell carcinoma.

High levels of CD163-positive TAMs and exhausted CD8-positive TILs could potentially affect efficacy results in metastatic RCC by reprogramming TAMs.